Last 7 days
4.7%
Last 30 days
-5%
Last 90 days
-21.3%
Trailing 12 Months
-67%
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -9.5% | 477,706,000 | 527,915,000 | 539,127,000 | 438,145,000 | 313,837,000 |
Operating Expenses | -35.8% | 2,686,658,000 | 4,187,094,000 | 3,571,957,000 | 2,884,012,000 | 2,142,304,000 |
S&GA Expenses | -35.2% | 1,429,799,000 | 2,206,982,667 | 1,665,349,333 | 862,952,000 | - |
R&D Expenses | -43.3% | 1,052,643,000 | 1,856,513,000 | 1,649,954,000 | 1,412,797,000 | 1,149,662,000 |
EBITDA | -15.1% | -3,490,597,000 | -3,033,922,000 | -2,220,765,145 | -1,818,701,000 | - |
EBITDA Margin | -17.5% | -6.61 | -5.63 | -5.07 | -5.80 | - |
Earnings Before Taxes | 40.0% | -2,121,399,000 | -3,538,153,000 | -2,971,682,000 | -2,355,962,000 | -1,838,122,000 |
EBT Margin | -21.6% | -6.70 | -5.51 | -5.50 | -5.86 | - |
Interest Expenses | 137.9% | 10,951,000 | 4,603,000 | 2,451,000 | 2,373,000 | - |
Net Income | 40.4% | -2,104,929,000 | -3,529,041,000 | -2,961,867,000 | -2,346,983,000 | -1,830,047,000 |
Net Income Margin | -21.7% | -6.68 | -5.49 | -5.48 | -5.83 | - |
Free Cahsflow | -9.9% | -344,778,000 | -313,676,000 | -311,411,562 | -310,339,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 35.7% | 2,539 | 1,871 | 1,994 | 2,058 | 2,071 |
Current Assets | -0.8% | 1,450 | 1,462 | 1,599 | 1,706 | 1,723 |
Cash Equivalents | 1.0% | 1,316 | 1,303 | 1,377 | 1,493 | 1,550 |
Inventory | -25.5% | 4.00 | 6.00 | 8.00 | 9.00 | 3.00 |
Net PPE | 67.8% | 315 | 188 | 176 | 149 | 146 |
Goodwill | 109.0% | 60.00 | 29.00 | 31.00 | 21.00 | 21.00 |
Liabilities | 86.3% | 803 | 431 | 427 | 444 | 504 |
Current Liabilities | 38.6% | 173 | 125 | 135 | 159 | 135 |
Shareholder's Equity | 21.0% | 1,736 | 1,435 | 1,567 | 1,614 | 1,505 |
Retained Earnings | -4.1% | -4,397 | -4,226 | -3,557 | -2,888 | -2,297 |
Additional Paid-In Capital | 8.2% | 6,136 | 5,669 | 5,098 | 4,471 | 3,805 |
Accumulated Depreciation | 6.7% | 83.00 | 78.00 | 70.00 | 61.00 | - |
Shares Outstanding | -0.3% | 1,631 | 1,636 | 1,607 | 1,611 | - |
Minority Interest | -100.0% | - | 5.00 | 32.00 | 33.00 | 62.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 19.4% | -252 | -313 | -289 | -225 | -253 |
Share Based Compensation | -43.4% | 1,931 | 3,414 | 2,851 | 2,259 | 1,606 |
Cashflow From Investing | 27.5% | -67.39 | -92.91 | -76.93 | -86.20 | -73.26 |
Cashflow From Financing | 799.0% | 95.00 | -13.64 | 1,535 | 1,533 | 1,534 |
Buy Backs | NaN% | 0.00 | 0.00 | 25.00 | - | - |
68.6%
68.6%
64.7%
Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | added | 3.76 | -32,456 | 41,653 | -% |
2023-03-17 | American Portfolios Advisors | added | 6.29 | 61,926 | 219,358 | 0.01% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | new | - | 118,109 | 118,109 | -% |
2023-03-13 | Claro Advisors LLC | sold off | -100 | -238,000 | - | -% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 19.65 | -224,061,000 | 412,659,000 | 0.43% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 23.12 | -92,526 | 184,474 | -% |
2023-03-08 | Capital Asset Advisory Services LLC | unchanged | - | -61,175 | 71,825 | 0.01% |
2023-03-06 | OLD MISSION CAPITAL LLC | new | - | 10,962 | 10,962 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -12.13 | -3,000 | 1,000 | -% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | added | 42.97 | -18,146 | 61,854 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | che austin | 6.3% | 99,857,282 | SC 13G/A | |
Feb 14, 2023 | knight thomas f. jr. | 5.0% | 74,936,116 | SC 13G/A | |
Feb 14, 2023 | anchorage capital group, l.l.c. | 4.83% | 69,904,593 | SC 13G/A | |
Feb 14, 2023 | viking global investors lp | 9.36% | 143,085,126 | SC 13G/A | |
Feb 13, 2023 | general atlantic, l.p. | 2.4% | 32,319,896 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 7.49% | 101,521,280 | SC 13G | |
Jan 25, 2023 | shetty reshma p. | 12.0% | 195,788,523 | SC 13D/A | |
Jan 25, 2023 | kelly jason r | 6.2% | 97,017,435 | SC 13D/A | |
Jan 23, 2023 | baillie gifford & co | 18.03% | 244,176,643 | SC 13G/A | |
Jul 01, 2022 | viking global investors lp | 9.7% | 115,084,128 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 31, 2023 | 4 | Insider Trading | |
Mar 31, 2023 | 4 | Insider Trading | |
Mar 31, 2023 | 4 | Insider Trading | |
Mar 30, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 30, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 29, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 29, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 24, 2023 | 4 | Insider Trading | |
Mar 24, 2023 | 4 | Insider Trading | |
Mar 24, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-23 | Shetty Reshma P. | sold | -47,363 | 1.258 | -37,650 | see remarks |
2023-03-23 | Canton Barry | sold | -47,363 | 1.258 | -37,650 | - |
2023-03-23 | Kelly Jason R | sold | -125,800 | 1.258 | -100,000 | see remarks |
2023-03-22 | Shetty Reshma P. | sold | -48,530 | 1.289 | -37,650 | see remarks |
2023-03-22 | Canton Barry | sold | -48,530 | 1.289 | -37,650 | - |
2023-03-22 | Kelly Jason R | sold | -128,500 | 1.285 | -100,000 | see remarks |
2023-03-16 | Kelly Jason R | sold | -131,500 | 1.315 | -100,000 | see remarks |
2023-03-16 | Canton Barry | sold | -49,509 | 1.315 | -37,650 | - |
2023-03-16 | Shetty Reshma P. | sold | -49,509 | 1.315 | -37,650 | see remarks |
2023-03-15 | Kelly Jason R | sold | -131,700 | 1.317 | -100,000 | see remarks |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||||||
Biosecurity revenue: | |||||||||
Total revenue | $ 477,706 | $ 313,837 | $ 76,657 | ||||||
Costs and operating expenses: | |||||||||
Research and development | 1,052,643 | 1,149,662 | 159,767 | ||||||
General and administrative expenses | 1,429,799 | 862,952 | 38,306 | ||||||
Total operating expenses | 2,686,658 | 2,142,304 | 213,684 | ||||||
Loss from operations | (2,208,952) | (1,828,467) | (137,027) | ||||||
Other income (expense): | |||||||||
Interest income | 20,262 | 837 | 2,582 | ||||||
Interest expense | (106) | (2,373) | (2,385) | ||||||
(Loss) gain on equity method investments: | (43,761) | (77,284) | (396) | ||||||
Loss on investments | (53,335) | (11,543) | (3,733) | ||||||
Change in fair value of warrant liabilities | 124,970 | 58,615 | 0 | ||||||
Gain on settlement of partnership agreement | 0 | 23,826 | 8,286 | ||||||
Gain on deconsolidation of subsidiaries | 31,889 | 0 | 0 | ||||||
Other income (expense), net | 7,634 | (1,733) | 7,839 | ||||||
Total other income (expense), net | 87,553 | (9,655) | 12,193 | ||||||
Loss before income taxes | (2,121,399) | (1,838,122) | (124,834) | ||||||
Income tax (benefit) provision | (15,027) | (1,480) | 1,889 | ||||||
Net loss | (2,106,372) | (1,836,642) | (126,723) | ||||||
Loss attributable to non-controlling interest | (1,443) | (6,595) | (114) | ||||||
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $ (2,104,929) | $ (1,830,047) | $ (126,609) | ||||||
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders (2): | |||||||||
Basic | $ (1.25) | $ (1.35) | $ (0.10) | ||||||
Diluted | $ (1.25) | $ (1.39) | $ (0.10) | ||||||
Weighted average common shares outstanding (2) | |||||||||
Basic | 1,679,061,465 | 1,359,848,803 | 1,274,766,915 | ||||||
Diluted | 1,679,838,849 | 1,360,373,343 | 1,274,766,915 | ||||||
Comprehensive loss: | |||||||||
Net loss | $ (2,106,372) | $ (1,836,642) | $ (126,723) | ||||||
Other comprehensive loss: | |||||||||
Foreign currency translation adjustment | (917) | (1,715) | |||||||
Total other comprehensive loss | (917) | (1,715) | |||||||
Comprehensive loss | (2,107,289) | (1,838,357) | (126,723) | ||||||
Product | |||||||||
Biosecurity revenue: | |||||||||
Total revenue | 35,455 | 23,040 | 8,707 | ||||||
Costs and operating expenses: | |||||||||
Cost of Biosecurity revenue | 20,646 | 20,017 | 6,705 | ||||||
Service | |||||||||
Biosecurity revenue: | |||||||||
Total revenue | 298,585 | 177,808 | 8,729 | ||||||
Costs and operating expenses: | |||||||||
Cost of Biosecurity revenue | 183,570 | 109,673 | 8,906 | ||||||
Foundry Revenue [Member] | |||||||||
Biosecurity revenue: | |||||||||
Total revenue | [1] | $ 143,666 | $ 112,989 | $ 59,221 | |||||
|
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,315,792 | $ 1,550,004 |
Accounts receivable, net | 80,907 | 131,544 |
Accounts receivable - related parties | 1,558 | 4,598 |
Inventory, net | 4,364 | 3,362 |
Prepaid expenses and other current assets | 47,458 | 33,537 |
Total current assets | 1,450,079 | 1,723,045 |
Property, plant, and equipment, net | 314,773 | 145,770 |
Operating lease right-of-use assets | 400,762 | 0 |
Investments | 112,188 | 102,037 |
Equity method investments | 1,543 | 13,194 |
Intangible assets, net | 111,041 | 21,642 |
Goodwill | 60,210 | 21,312 |
Other non-current assets | 88,725 | 43,990 |
Total assets | 2,539,321 | 2,070,990 |
Current liabilities: | ||
Accounts payable | 10,451 | 8,189 |
Deferred revenue (includes $10,309 and $12,502 from related parties) | 47,817 | 33,240 |
Accrued expenses and other current liabilities | 114,694 | 93,332 |
Total current liabilities | 172,962 | 134,761 |
Non-current liabilities: | ||
Deferred rent, net of current portion | 0 | 18,746 |
Deferred revenue, net of current portion (includes $131,188 and $148,319 from related parties) | 174,767 | 155,991 |
Operating lease liabilities, non-current | 413,256 | 0 |
Lease financing obligation | 22,283 | |
Warrant liabilities | 10,868 | 135,838 |
Other non-current liabilities | 31,191 | 35,992 |
Total liabilities | 803,044 | 503,611 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | 0 | 0 |
Common stock $0.0001 par value (Note 12) | 190 | 161 |
Additional paid-in capital | 6,136,378 | 3,804,844 |
Accumulated deficit | (4,397,659) | (2,297,925) |
Accumulated other comprehensive loss | (2,632) | (1,715) |
Total Ginkgo Bioworks Holdings, Inc. stockholders’ equity | 1,736,277 | 1,505,365 |
Non-controlling interest | 0 | 62,014 |
Total stockholders’ equity | 1,736,277 | 1,567,379 |
Total liabilities and stockholders’ equity | $ 2,539,321 | $ 2,070,990 |